Zomedica Corp.

NYSEAM:ZOM Stock Report

Market Cap: US$122.8m

Zomedica Management

Management criteria checks 4/4

Zomedica's CEO is Larry Heaton, appointed in Oct 2021, has a tenure of 3.25 years. total yearly compensation is $651.40K, comprised of 67.3% salary and 32.7% bonuses, including company stock and options. directly owns 0.051% of the company’s shares, worth $62.65K. The average tenure of the management team and the board of directors is 3 years and 4.4 years respectively.

Key information

Larry Heaton

Chief executive officer

US$651.4k

Total compensation

CEO salary percentage67.3%
CEO tenure3.3yrs
CEO ownership0.05%
Management average tenure3yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Larry Heaton's remuneration changed compared to Zomedica's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$56m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$651kUS$438k

-US$35m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$1mUS$400k

-US$17m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$18m

Dec 31 2021US$5mUS$100k

-US$50m

Compensation vs Market: Larry's total compensation ($USD651.40K) is about average for companies of similar size in the US market ($USD643.82K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.

CEO

Larry Heaton (67 yo)

3.3yrs

Tenure

US$651,396

Compensation

Mr. Larry C. Heaton II serves as President at Zomedica Corp. since October 1, 2021 and serves as it’s Chief Executive Officer since November 1, 2021 and serves as its Director since June 2023. He served as...

Leadership Team

NamePositionTenureCompensationOwnership
Larry Heaton
President3.3yrsUS$651.40k0.051%
$ 62.6k
Russell Klass
Senior Vice President of Sales1.2yrsUS$537.83k0.15%
$ 188.0k
Scott Jordan
EVP of Finance & CFOno datano datano data
Anthony Blair
Chief Operating Officer3yrsno data0.041%
$ 50.1k
Karen DeHaan-Fullerton
General Counsel & Corporate Secretary2.7yrsno data0%
$ 0
Nicole Westfall
Senior Vice President of Marketing3yrsno datano data
Kristin Domanski
Vice President of Human Resources3yrsno datano data
Greg Blair
Senior Vice President of Business Development & Strategic Planningno datano datano data
Mike Zuehlke
Vice President of Finance & Corporate Controllerno datano datano data
Robert DiMarzo
Consultant6.6yrsUS$578.27kno data

3.0yrs

Average Tenure

60yo

Average Age

Experienced Management: ZOM's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Larry Heaton
President1.6yrsUS$651.40k0.051%
$ 62.6k
Johnny Powers
Independent Director5.4yrsUS$50.00k0.25%
$ 303.9k
Robert Cohen
Director4.3yrsUS$50.00k0%
$ 0
Jeffrey Rowe
Independent Chairman8.8yrsUS$65.00k0.11%
$ 140.4k
Sean Whelan
Independent Director3.3yrsUS$55.00k0%
$ 0
Ann Donoghue
Member of Scientific Advisory Boardno datano datano data
Rodney Williams
Independent Director8.8yrsUS$55.00k0.017%
$ 20.3k
Christopher MacLeod
Independent Director4.5yrsUS$50.00k0%
$ 0
Marc Bailie
Member of Scientific Advisory Boardno datano datano data
Pamela Nichols
Independent Director2.4yrsUS$50.00k0%
$ 0

4.4yrs

Average Tenure

62yo

Average Age

Experienced Board: ZOM's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 21:28
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zomedica Corp. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerNOBLE Capital Markets, Inc.